ASCVD Best Practices Learning Collaborative
AMGA Foundation, with support from Amgen and Novartis, launched a 15-month initiative focused on helping medical groups develop strategies to improve the management and treatment of patients with established atherosclerotic cardiovascular disease (ASCVD).
The ASCVD Best Practices Learning Collaborative is designed to provide a platform for participating organizations to improve their clinical performance in the treatment of established ASCVD through the development and implementation of quality improvement projects, best practice sharing, and peer-to-peer learning.
Fifteen healthcare organizations were selected to participate in the Collaborative:
|
|
September 13, 2022 - ASCVD Virtual Discussion Forum Meeting Summary
The Atherosclerotic Cardiovascular Disease (ASCVD) Virtual Discussion Forum occurred on September 13, 2022. This 90-minute moderated session, in collaboration with Novartis and AMGEN, engaged Collaborative participating organizations in an interactive discussion focused on helping medical groups develop strategies to improve the management and treatment of patients with established ASCVD. The top four challenges or motivating needs in successful ASCVD care were discussed, including patient awareness and education, affordable treatment for high-risk patients, care coordination, and disparities in care.
Download the ASCVD Meeting Summary
ASCVD Best Practices Learning Collaborative Advisory Committee
- Parag Agnihotri, M.D.
Chief Medical Officer, Population Health Services, UC San Diego Health
- Amy M. Ahnert, M.D.
Practice Leader and Director of Clinical Cardiology, Lehigh Valley Heart and Vascular Institute, Cedar Crest; Director, Women’s Heart and Vascular Program, Lehigh Heart and Vascular Institute, Cedar Crest; and Co-Director, Cardio-Obstetrics Program
- Scott Berkowitz, M.D., M.B.A.
Chief Population Health Officer and Associate Professor of Medicine, John Hopkins Medicine
- Nihar R. Desai, M.D., M.P.H.
Associate Professor and Vice Chief, Section of Cardiovascular Medicine, Yale University School of Medicine
- Bethany Kalich, Pharm.D.
Medical Director, Cardiovascular US Medical Organization, Amgen
- Liana Spano-Brennan, D.O., FACC
Cardiologist, Summit Health
- Jennifer Van Meter, Pharm.D.
Director, Healthcare Association Engagement and Innovation, Novartis
If you have questions or need further information about this collaborative, contact Erin Leaver-Schmidt at eleaver-schmidt@amga.org or by phone at 703.838.0033 ext. 390.
